⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 3, 2024Journal of Surgical Oncology

Barriers to resection following neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma: A national and local perspective

Marc W. Fromer Tyler J. Mouw Charles R. Scoggins Michael E. Egger Prejesh Philips Kelly M. McMasters Robert C.G. Martin

View Full Paper

Ask AI

Bookmark

Share

Abstract

Neoadjuvant chemotherapy (NAC) use for pancreatic ductal adenocarcinoma (PDAC) has increased, but some patients never get resection following NAC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fromer et al. (2024) studied this question.

synapsesocial.com/papers/68e66722b6db6435875f3155 https://doi.org/10.1002/jso.27697

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Neoadjuvant chemotherapy is associated with improved disease‐free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resection2024 · 4 citations
2Survival outcomes in localized pancreatic cancer treated with neoadjuvant chemotherapy (NAC).Retrospective Study · 2026
3Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer2025
4Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten?2025 · 1 citations
5Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma2024 · 2 citations